胰岛素样生长因子-I受体异常激活与肝癌靶向治疗  

Abnormal activation of insulin-like growth factor-I receptor in hepatocellular carcinoma and potential of IGF-IR targeted therapy

作　　者：严晓娣[1] 董志珍[1] 姚登福[1] 

机构地区：[1]南通大学附属医院临床医学研究中心,江苏南通226001

出　　处：《临床肝胆病杂志》2013年第6期473-476,共4页Journal of Clinical Hepatology

基　　金：南通市社会事业科技创新计划(HS2012039);江苏省临床医学科技专项(BL2012053)

摘　　要：肝细胞恶性转化和癌变过程中,胰岛素样生长因子-I受体(IGF-IR)异常活化。IGF-IR过表达既可作为肝癌早期诊断的标志,又可作为肝癌靶向治疗的新靶点,且具有应用前景。本文对IGF-IR信号通路异常激活及分子靶向治疗肝癌等的研究进展作了综述。Abnormal activation of the insulin- like growth factor- I receptor （IGF- IR） occurs during malignant transformation of hepatocytes and during hepatocarcinogenesis. IGF - IR overexpression has been proposed as a diagnostic biomarker for early - stage hepatocellular carcinoma （ HCC ） as well as a novel target for HCC therapy. This review summarizes the recent research of the IGF - IR signaling pathway abnormal activation in HCC and the results of molecular targeting studies.

关 键 词：肝肿瘤 受体 IGF 1型 抗体 单克隆 微RNAS 

分 类 号：R735.7[医药卫生—肿瘤]